BioLineRx Ltd. (BLRX) Form 6-K — May 27, 2026
BioLineRx reported a net loss of $2.6 million for Q1 2026, driven by a 56% increase in R&D expenses to $2.5 million as it advances its new GLIX1 program. Revenue rose 87% year-over-year to $0.5 million, primarily from royalties on APHEXDA sales by partner Ayrmid. The company highlighted significant clinical progress, announcing the first patient dosed in the Phase 1/2a trial for GLIX1 in glioblastoma in April 2026. New preclinical data demonstrated potent anti-tumor effects in TMZ-resistant patient-derived xenograft models, supporting the asset's potential in this aggressive cancer type.
Key figures
- Revenue
- 477000
- Revenue Yoy
- 86.7%
- Total Assets
- 40905000
- Cash Position
- 17400000
- Rd expenses
- 2528000
- G a expenses
- 858000
- Royalty revenue
- 477000
- Aphexda sales q1
- 2700000
- Aphexda royalty q1
- 500000
- Blackrock loan maturity
- December 1, 2027
- Tetragon total commitment
- 5000000
- Tetragon investment to date
- 2600000
- Blackrock loan interest rate
- 9.5%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.